LUPIN LIMITED

SAFETY DATA SHEET

Section 1: Identification

Section 1, Identification

Material

Bekyree™
desogestrel and ethinyl estradiol tablets USP, 0.15 mg/0.02 mg
and ethinyl estradiol tablets USP, 0.01 mg

Manufacturer

Lupin Limited
Goa - 403722
India

Distributor

Lupin Pharmaceuticals, Inc.
111 South Calvert Street,
Harborplace Tower, 21st Floor,
Baltimore, Maryland 21202
United States

Tel. 001-410-576-2000
Fax. 001-410-576-2221

Section 2: Hazard(s) Identification

Section 2, Hazard(s) identification

Fire and Explosion

Expected to be non-combustible.

Health

Oral contraceptives should not be used in women who currently have the following conditions:

- Thrombophlebitis or thromboembolic disorders
- A past history of deep vein thrombophlebitis or thromboembolic disorders
- Cerebral vascular or coronary artery disease
- Known or suspected carcinoma of the breast
- Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia
- Undiagnosed abnormal genital bleeding
- Cholestatic jaundice of pregnancy or jaundice with prior pill use
- Hepatic adenomas or carcinomas
- Known or suspected pregnancy

Environment

No information is available about the potential of this product to produce adverse environmental effects.
Section 3: Composition/Information on Ingredients

Ingredients

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Norethindrone USP</td>
<td>68-22-4</td>
</tr>
<tr>
<td>Ethinyl Estradiol USP</td>
<td>57-63-6</td>
</tr>
</tbody>
</table>

Section 4: First-Aid Measures

Ingestion

If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.

Inhalation

Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.

Skin Contact

Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.

Eye Contact

Flush eyes with plenty of water. Get medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment

Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc.

OVERDOSAGE

Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in females.

Section 5: Fire-Fighting Measures

Fire and Explosion Hazards

Assume that this product is capable of sustaining combustion.

Extinguishing Media

Water spray, carbon dioxide, dry chemical powder or appropriate foam.

Special Firefighting Procedures

For single units (packages): No special requirements needed.
For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended for firefighters.

**Hazardous Combustion Products**
Hazardous combustion or decomposition products are expected when the product is exposed to fire.

---

### Section 6: Accidental Release Measures

#### Section 6, Accidental release measures

**Personal Precautions**
Wear protective clothing and equipment consistent with the degree of hazard.

**Environmental Precautions**
For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.

**Clean-up Methods**
Collect and place it in a suitable, properly labeled container for recovery or disposal.

---

### Section 7: Handling and Storage

#### Section 7, Handling and storage

**Handling**
No special control measures required for the normal handling of this product.

Normal room ventilation is expected to be adequate for routine handling of this product.

**Storage**
Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F). [see USP Controlled Room Temperature].

---

### Section 8: Exposure Controls/ Personal Protection

#### Section 8, Exposure controls/personal protection

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.
### Section 9: Physical and Chemical Properties

#### Section 9, Physical and chemical properties

**Physical Form**

Bekyree (desogestrel and ethinyl estradiol tablets USP and ethinyl estradiol tablets USP) are available in cartons (NDC 68180-880-13) containing three pouches, each pouch (NDC 68180-880-11) containing a wallet of 28 tablets (NDC 68180-880-11).

Each wallet (28 tablets) contains in the following order:
- 21 white, round, biconvex film-coated tablets, debossed with “LU” on one side and “K21” on the other side each containing desogestrel 0.15 mg and ethinyl estradiol 0.02 mg.
- 2 inert green, round, biconvex film-coated tablets, debossed with “LU” on one side and “L22” on the other side.
- 5 yellow, round, biconvex film-coated tablets, debossed with “LU” on one side and “K22” on the other side each containing ethinyl estradiol 0.01 mg.

### Section 10: Stability and Reactivity

#### Section 10, Stability and reactivity

Stable under recommended storage conditions.

### Section 11: Toxicological Information

#### Section 11, Toxicological information

**Carcinoma of the reproductive organs and breasts**

Numerous epidemiologic studies have been performed on the incidence of breast, endometrial, ovarian, and cervical cancer in women using oral contraceptives. While there are conflicting reports, most studies suggest that the use of oral contraceptives is not associated with an overall increase in the risk of developing breast cancer. Some studies have reported an increased relative risk of developing breast cancer, particularly at a younger age. This increased relative risk appears to be related to duration of use (36-43, 79-89).

Some studies suggest that oral contraceptive use has been associated with an increase in the risk of cervical intra-epithelial neoplasia in some populations of women (45-48). However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors.

### Section 12: Ecological Information

#### Section 12: Ecological Information

No relevant studies identified.
Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

Section 14: Transport Information

Section 14: Transport Information

IATA/ICAO - Not Regulated
- IATA Proper shipping Name : N/A
- IATA UN/ID No : N/A
- IATA Hazard Class : N/A
- IATA Packaging Group : N/A
- IATA Label : N/A

IMDG - Not Regulated
- IMDG Proper shipping Name : N/A
- IMDG UN/ID No : N/A
- IMDG Hazard Class : N/A
- IMDG Flash Point : N/A
- IMDG Label : N/A

DOT - Not Regulated
- DOT Proper shipping Name : N/A
- DOT UN/ID No : N/A
- DOT Hazard Class : N/A
- DOT Flash Point : N/A
- DOT Packing Group : N/A
- DOT Label : N/A

Section 15: Regulatory Information

Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

Section 16: Other Information

Section 16, Other information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this MSDS.